RNF213 sirna

RNF213 siRNA (Human)

Cat. Num. AAA8230213

• Gene Names: RNF213; ALO17; MYMY2; MYSTR; NET57; C17orf27; KIAA1618
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: RNF213; RNF213 siRNA (Human); ALO17; C17orf27; KIAA1554; KIAA1618; MYSTR; E3 ubiquitin-protein ligase RNF213; ALK lymphoma oligomerization partner on chromosome 17; Mysterin; RING finger protein 213; RNF213 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: RNF213 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 5207

• Applicable Applications for RNF213 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human RNF213 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for RNF213 sirna

siRNA to inhibit RNF213 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 597709777
• NCBI GeneID: 57674
• NCBI Accession #: NP_001243000.2
• NCBI GenBank Nucleotide #: NM_001256071.2
• UniProt Accession #: Q63HN8; Q658P6; Q69YK7; Q6MZR1; Q8IWF4; Q8IZX1; Q8IZX2; Q8N406; Q8TEU0; C9JCP4; D6RI12; F8WKS1
• Molecular Weight: 64,260 Da
• NCBI Official Full Name: E3 ubiquitin-protein ligase RNF213 isoform 3
• NCBI Official Synonym Full Names: ring finger protein 213
• NCBI Official Symbol: RNF213
• NCBI Official Synonym Symbols: ALO17; MYMY2; MYSTR; NET57; C17orf27; KIAA1618
• NCBI Protein Information: E3 ubiquitin-protein ligase RNF213
• UniProt Protein Name: E3 ubiquitin-protein ligase RNF213
• Protein Family: E3 ubiquitin-protein ligase
• UniProt Gene Name: RNF213
• UniProt Synonym Gene Names: ALO17; C17orf27; KIAA1554; KIAA1618; MYSTR
• UniProt Entry Name: RN213_HUMAN

NCBI Description

This gene encodes a protein containing a C3HC4-type RING finger domain, which is a specialized type of Zn-finger that binds two atoms of zinc and is thought to be involved in mediating protein-protein interactions. The protein also contains an AAA domain, which is associated with ATPase activity. This gene is a susceptibility gene for Moyamoya disease, a vascular disorder of intracranial arteries. This gene is also a translocation partner in anaplastic large cell lymphoma and inflammatory myofibroblastic tumor cases, where a t(2;17)(p23;q25) translocation has been identified with the anaplastic lymphoma kinase (ALK) gene on chromosome 2, and a t(8;17)(q24;q25) translocation has been identified with the MYC gene on chromosome 8. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2011]

Uniprot Description

RNF213: Probable E3 ubiquitin-protein ligase that may play a role in angiogenesis. May also have an ATPase activity. Defects in RNF213 are the cause of susceptibility to Moyamoya disease type 2 (MYMY2). A progressive cerebral angiopathy characterized by bilateral intracranial carotid artery stenosis and telangiectatic vessels in the region of the basal ganglia. The abnormal vessels resemble a 'puff of smoke' (moyamoya) on cerebral angiogram. Affected individuals can develop transient ischemic attacks and/or cerebral infarction, and rupture of the collateral vessels can cause intracranial hemorrhage. Hemiplegia of sudden onset and epileptic seizures constitute the prevailing presentation in childhood, while subarachnoid bleeding occurs more frequently in adults. A chromosomal aberration involving ALO17 is associated with anaplastic large-cell lymphoma (ALCL). Translocation t(2;17)(p23;q25) with ALK. 4 isoforms of the human protein are produced by alternative splicing.

Protein type: Oncoprotein; EC 6.3.2.-; Ubiquitin conjugating system

Chromosomal Location of Human Ortholog: 17q25.3

Cellular Component: membrane; cytoplasm; nucleolus

Molecular Function: zinc ion binding; ATPase activity; ubiquitin-protein ligase activity; ligase activity

Biological Process: protein autoubiquitination; protein ubiquitination